These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 24661905)

  • 1. Partial versus maximal forced exhalations in COPD: enhanced signal detection for novel therapies.
    Martinot JB; Chambellan A; Kays C; Silkoff PE; Guenard H
    Pulm Pharmacol Ther; 2014 Oct; 29(1):58-65. PubMed ID: 24661905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute bronchodilator responses to β2-agonist and anticholinergic agent in COPD: Their different associations with exacerbation.
    Konno S; Makita H; Suzuki M; Shimizu K; Kimura H; Kimura H; Nishimura M;
    Respir Med; 2017 Jun; 127():14-20. PubMed ID: 28502414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bronchodilator response of advanced lung function parameters depending on COPD severity.
    Jarenbäck L; Eriksson G; Peterson S; Ankerst J; Bjermer L; Tufvesson E
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2939-2950. PubMed ID: 27932874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of dry powder versus nebulized beta-agonist in patients with COPD who have suboptimal peak inspiratory flow rate.
    Mahler DA; Waterman LA; Ward J; Gifford AH
    J Aerosol Med Pulm Drug Deliv; 2014 Apr; 27(2):103-9. PubMed ID: 23745526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Salbutamol Nebulization During Noninvasive Ventilation in Exacerbated Chronic Obstructive Pulmonary Disease Patients: A Randomized Controlled Trial.
    Bodet-Contentin L; Guillon A; Boulain T; Frat JP; Garot D; Le Pennec D; Vecellio L; Ehrmann S; Giraudeau B; Tavernier E; Dequin PF
    J Aerosol Med Pulm Drug Deliv; 2019 Jun; 32(3):149-155. PubMed ID: 30589607
    [No Abstract]   [Full Text] [Related]  

  • 6. Measures of bronchodilator response of FEV
    Torén K; Bake B; Olin AC; Engström G; Blomberg A; Vikgren J; Hedner J; Brandberg J; Persson HL; Sköld CM; Rosengren A; Bergström G; Janson C
    Int J Chron Obstruct Pulmon Dis; 2017; 12():973-980. PubMed ID: 28356729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Small airway dysfunction and flow and volume bronchodilator responsiveness in patients with chronic obstructive pulmonary disease.
    Pisi R; Aiello M; Zanini A; Tzani P; Paleari D; Marangio E; Spanevello A; Nicolini G; Chetta A
    Int J Chron Obstruct Pulmon Dis; 2015; 10():1191-7. PubMed ID: 26150710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomised, double-blind, four-way, crossover trial comparing the 24-h FEV1 profile for once-daily versus twice-daily treatment with olodaterol, a novel long-acting β2-agonist, in patients with chronic obstructive pulmonary disease.
    Joos GF; Aumann JL; Coeck C; Korducki L; Hamilton AL; Kunz C; Aalbers R
    Respir Med; 2015 May; 109(5):606-15. PubMed ID: 25776199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of COPD in a high-risk population: should the diagnostic work-up include bronchodilator reversibility testing?
    Kjeldgaard P; Dahl R; Løkke A; Ulrik CS
    Int J Chron Obstruct Pulmon Dis; 2015; 10():407-14. PubMed ID: 25759573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomised, placebo-controlled, Phase II, dose-ranging trial of once-daily treatment with olodaterol, a novel long-acting β2-agonist, for 4 weeks in patients with chronic obstructive pulmonary disease.
    Maleki-Yazdi MR; Beck E; Hamilton AL; Korducki L; Koker P; Fogarty C
    Respir Med; 2015 May; 109(5):596-605. PubMed ID: 25829298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of long-acting bronchodilators and prednisolone on inspiratory lung function parameters in stable COPD.
    Ramlal SK; Visser FJ; Hop WC; Dekhuijzen PN; Heijdra YF
    Pulm Pharmacol Ther; 2014 Aug; 28(2):158-64. PubMed ID: 24076367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic treatment with indacaterol and airway response to salbutamol in stable COPD.
    Cazzola M; Rogliani P; Ruggeri P; Segreti A; Proietto A; Picciolo S; Matera MG
    Respir Med; 2013 Jun; 107(6):848-53. PubMed ID: 23490225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing the reversibility of airway obstruction.
    Pellegrino R; Rodarte JR; Brusasco V
    Chest; 1998 Dec; 114(6):1607-12. PubMed ID: 9872196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies.
    Kerwin EM; Gotfried MH; Lawrence D; Lassen C; Kramer B
    Clin Ther; 2011 Dec; 33(12):1974-84. PubMed ID: 22177371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Spirometric reversibility to salbutamol in chronic obstructive pulmonary disease (COPD). Differential effects on FEV1 and on lung volumes].
    Manríquez J; Díaz O; Borzone G; Lisboa C
    Rev Med Chil; 2004 Jul; 132(7):787-93. PubMed ID: 15379324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bronchodilator reversibility in asthma and COPD: findings from three large population studies.
    Janson C; Malinovschi A; Amaral AFS; Accordini S; Bousquet J; Buist AS; Canonica GW; Dahlén B; Garcia-Aymerich J; Gnatiuc L; Kowalski ML; Patel J; Tan W; Torén K; Zuberbier T; Burney P; Jarvis D
    Eur Respir J; 2019 Sep; 54(3):. PubMed ID: 31221806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison between inhaled salmeterol and theophylline in the short-term treatment of stable chronic obstructive pulmonary disease.
    Broseghini C; Testi R; Polese G; Tosatto R; Rossi A
    Pulm Pharmacol Ther; 2005; 18(2):103-8. PubMed ID: 15649852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
    Boscia JA; Pudi KK; Zvarich MT; Sanford L; Siederer SK; Crim C
    Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prevalence of bronchodilator responsiveness of the small airway (using mid-maximal expiratory flow) in COPD - a retrospective study.
    Alobaidi NY; Almeshari MA; Stockley JA; Stockley RA; Sapey E
    BMC Pulm Med; 2022 Dec; 22(1):493. PubMed ID: 36585669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPD.
    Kerwin EM; Scott-Wilson C; Sanford L; Rennard S; Agusti A; Barnes N; Crim C
    Respir Med; 2013 Apr; 107(4):560-9. PubMed ID: 23352226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.